Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-01-25

FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)

View source ↗

Summary

FDA approves a supplemental application for divalproex sodium submitted by Ajanta Pharma USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DIVALPROEX SODIUM (divalproex sodium)

Snippet

SUPPL AP for DIVALPROEX SODIUM (DIVALPROEX SODIUM)